All In Biotech

Drug Trial Radar · NCT03560193

Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery

An Open Label, Multicenter, Randomized Trial of 2% Chlorhexidine-70% Isopropanol vs 5% Povidone Iodine-69% Ethanol for Skin Antisepsis in Reducing Surgical-site Infection After Cardiac Surgery

Last checked: Nov 19, 2026Latest source record: Jun 13, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,316 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,316

Actual

Start

Sep 10, 2018

Primary completion

May 25, 2022

Study completion May 25, 2022

Sponsor

Lead sponsor
Poitiers University HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 18, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Despite completion of more than 9 million procedures each year in France, the best antiseptic solution to be used for preparing the skin to reduce risk of surgical site infection (SSI) remains unknown. 2% Chlorhexidine gluconate (CHG)-alcohol is superior to Povidone Iodine (PVI)-alcohol for short term vascular catheter care (Mimoz O, Lancet 2015; Pages J, Intensive Care Med 2016), but studies comparing both antiseptic solutions for clean-contaminated surgical procedures led to conflicting results. The present study will be the first large scale multicenter randomized controlled trial adequately powered to compare efficacy and safety of CHG-alcohol over PVI-alcohol in reducing SSI after clean surgery. A clean surgery was chosen because pathogens involved in SSI mostly originate from skin. Therefore, optimisation of skin disinfection before surgery has the potential to reduce the incidence of SSI. Cardiac surgery was chosen because SSI may be severe, diagnosis of SSI is easy to monitor and to define and infections arise earlier than other frequent clean surgeries using implants such as orthopaedic or vascular surgery. The incidence of reoperation for any purpose will be used as the main objective because there are easy to track and define and are less susceptible to interpretation in an open trial than superficial SSI. According to CDC criteria, patients will be monitored up to Day 90 because mediastinitis after cardiac surgery may occur after the usual 30-day SSI surveillance period.

Conditions

  • Cardiac Surgery in Adult Patient

Interventions

  • 2%Chlorhexidine-70%IsopropanolDrug

    2% Chlorhexidine-70% isopropanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes

  • 5%Povidone Iodine- 69%EthanolDrug

    5%Povidone Iodine- 69%Ethanol will be used to disinfect the skin before Cardiac Surgery and during all dressing changes

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of any re-sternotomy occurring between Day 0 and Day 90 after surgeryTime frame: 90 days
  2. Incidence of any reoperation on saphen venous/radial artery site occurring between Day 0 and Day 30 after surgery.Time frame: 30 days

Locations

8 sites in 1 country. Site status is shown where the registry gives one.

  • University Hospital of Clermont-Ferrand

    Clermont-Ferrand, France

  • University Hospital of Nantes

    Nantes, France

  • La Pitié Salpétrière Hospital

    Paris, France

  • Institut Mutualiste Montsouris

    Paris, France

  • University Hospital of Poitiers

    Poitiers, France

  • University Hospital of Rennes

    Rennes, France

  • CHRU de Strasbourg

    Strasbourg, France

  • CHU de Toulouse

    Toulouse, France

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.